Marlowe (MRL)

Sector:

Support

Index:

FTSE AIM 100

327.00p
   
  • Change Today:
      2.00p
  • 52 Week High: 612.00p
  • 52 Week Low: 295.00p
  • Currency: UK Pounds
  • Shares Issued: 80.44m
  • Volume: 36,510
  • Market Cap: £263.04m

Optima Health secures first licence deal for DART tool

By Josh White

Date: Tuesday 11 Feb 2025

LONDON (ShareCast) - (Sharecast News) - Optima Health announced on Tuesday that it has secured its first licence agreement for its proprietary 'Digital Assessment Routing Tool' (DART) with Mersey & West Lancashire Teaching Hospitals NHS Trust.
The firm, demerged from its AIM colleague Marlowe last year, said the deal followed a successful four-month quality improvement study that demonstrated DART's effectiveness in improving patient safety, pathway efficiency, cost savings, and patient and clinician satisfaction.

DART, which is fully owned by Optima, is DTAC-certified and listed on the NHS Innovation Service.

The company said the tool provides a digital first point of contact for patients self-referring for musculoskeletal care, offering an alternative to clinician-led triage.

It said the system assesses patients in an average of eight minutes, and directs them to the appropriate care pathway based on urgency and complexity, in line with the NHS's 'Getting It Right First Time' approach.

The agreement had generated significant interest from other NHS musculoskeletal services, the board explained, creating a new sales pipeline for Optima Health.

Optima said it sees potential for DART to support NHS efforts in reducing patient waiting lists.

DART had undergone substantial investment and development, with validation conducted in collaboration with Queen Mary University of London.

"We are excited to announce this first licence today for Optima's proprietary tool, DART," said chief executive officer Jonathan Thomas.

"Whilst the value of this initial licence is not material in the context of the group's overall revenue and profits, it aligns with the company's growth strategy to expand into adjacent markets.

"Following the successful four-month quality improvement study, we have received significant interest from other NHS trusts and breaking into this new market, as planned, will provide a healthy new sales pipeline for Optima Health."

At 1204 GMT, shares in Optima Health were up 1.02% at 172.75p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Marlowe Market Data

Currency UK Pounds
Share Price 327.00p
Change Today 2.00p
% Change 0.62 %
52 Week High 612.00p
52 Week Low 295.00p
Volume 36,510
Shares Issued 80.44m
Market Cap £263.04m

Marlowe Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
87.11% above the market average87.11% above the market average87.11% above the market average87.11% above the market average87.11% above the market average
77.53% above the sector average77.53% above the sector average77.53% above the sector average77.53% above the sector average77.53% above the sector average
Price Trend
40.24% below the market average40.24% below the market average40.24% below the market average40.24% below the market average40.24% below the market average
31.25% below the sector average31.25% below the sector average31.25% below the sector average31.25% below the sector average31.25% below the sector average
Income
64.99% below the market average64.99% below the market average64.99% below the market average64.99% below the market average64.99% below the market average
63.33% below the sector average63.33% below the sector average63.33% below the sector average63.33% below the sector average63.33% below the sector average
Growth
13.00% above the market average13.00% above the market average13.00% above the market average13.00% above the market average13.00% above the market average
20.88% above the sector average20.88% above the sector average20.88% above the sector average20.88% above the sector average20.88% above the sector average

What The Brokers Say

Strong Buy 3
Buy 2
Neutral 2
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Marlowe Dividends

  Latest Previous
  Special Interim
Ex-Div 13-Jun-24 n/a
Paid 05-Jul-24 n/a
Amount 155.00p 0.000p

Trades for 01-Apr-2025

Time Volume / Share Price
16:43 303 @ 326.00p
16:43 303 @ 326.00p
16:40 272 @ 326.00p
16:38 2,200 @ 325.35p
16:38 5,200 @ 325.15p

Marlowe Key Personnel

CFO Adam Councell

Top of Page